Trial of MK-2206 + Endocrine Treatment in Patients With Hormone Receptor Positive Breast Cancer
Status:
Withdrawn
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
This is a phase II Trial of MK-2206 in combination with Endocrine Therapy in patients with
Hormone Receptor Breast Cancer. After the maximum tolerated dose is determined in the phase
1b trial (under a separate NCT number), efficacy will be evaluated among 17 patients.